NIH study shows HIV prevention drug safe for teen males

  • Published in Health

Researchers at the National Institutes of Health have concluded that an HIV prevention drug commonly used by adults appears to be safe for adolescent males aged 15 to 17.

The study examined the safety and effectiveness of Truvada, a Pre-Exposure Prophylaxis drug designed to preventively reduce the risk of an HIV infection.

"This is the first study on the safety and implementation of PrEP among adolescent men who have sex with men," said Dr. Bill Kapogiannis, one of the authors of the study and a researcher at NIH's National Institute of Child Health and Human Development. "It demonstrates that adolescents who are at risk for HIV and are thus likely to benefit from PrEP can be successful at participating in biomedical HIV prevention research," he added.

Subscribe to this RSS feed